| VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Ce…K262807 · LON | BIOMERIEUX, Inc. | 510(k) | Nov 4, 2026FDA decision date |
| VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)K260283 · LON | bioMerieux, Inc. | 510(k) | Oct 1, 2026FDA decision date |
| VITEK 2 AST-N461 TEST KIT, GRAM NEGATIVE SUSCEPTIBILITY TESTING - AUTOMATED, Reference Number 424811Z-3231-2026 · LON | Biomerieux Inc | Recall | Sep 18, 2026FDA classification date |
| VITEK 2 AST-N447 TEST KIT
Product reference 424620Z-2715-2026 · LON | Biomerieux Inc | Recall | Jul 9, 2026FDA classification date |
| VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystemK260160 · SAN | bioMerieux, Inc. | 510(k) | Jul 8, 2026FDA decision date |
| VITEK 2 AST-Streptococcus Inducible Clindamycin ResistanceK260282 · LON | bioMerieux, Inc. | 510(k) | Apr 15, 2026FDA decision date |
| VITEK 2 Gram-negative Susceptibility Cards Containing
o Polymyxin B (pb02n)
o Ceftazidime/avibactam (cza02n)
o Meropenem/Vaborbactam (mev01n)
o I…Z-1236-2026 · LTW | Biomerieux Inc | Recall | Feb 2, 2026FDA classification date |
| VITEK 2 Gram-negative AST Test Kits (Cards) containing Colistin formulation cs02n.
VITEK 2 is an automated system consisting of instruments, sof…Z-2671-2025 · LON | bioMerieux, Inc. | Recall | Sep 29, 2025FDA classification date |
| VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)K251579 · LON | bioMerieux, Inc. | 510(k) | Aug 21, 2025FDA decision date |
| VITEK COMPACT PROK234012 · LON | bioMerieux, Inc. | 510(k) | Mar 14, 2025FDA decision date |
| VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)K232967 · NGZ | bioMerieux, Inc. | 510(k) | Jun 12, 2024FDA decision date |
| VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)K232963 · NGZ | bioMerieux, Inc. | 510(k) | Jun 7, 2024FDA decision date |
| VIDAS TBI (GFAP, UCH-L1)K240279 · QAT | bioMerieux, Inc. | 510(k) | May 1, 2024FDA decision date |
| VITEK 2 - AST Test kits (in vitro diagnostic test cards for antimicrobial susceptibility):
a) AST-N334, REF 418984;
b) AST-GN95, REF 421982;
…Z-1464-2024 · LON | Biomerieux Inc | Recall | Apr 25, 2024FDA classification date |
| VITEK 2 AST-Gram Positive Lefamulin (<=0.03 - >=4 µg/mL)K234000 · LON | bioMerieux, Inc. | 510(k) | Mar 11, 2024FDA decision date |
| VITEK 2 AST-Streptococcus Penicillin (<=0.06 - =>8 µg/mL), VITEK 2 Streptococcus Penicillin (<=0.06 - >=8 µg/mL), VITEK 2 Streptococcus Penicilli…K232201 · LON | bioMerieux, Inc. | 510(k) | Oct 23, 2023FDA decision date |
| VITEK 2 AST-Gram Positive Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP DaptomycinK230864 · LON | bioMerieux, Inc. | 510(k) | Jul 5, 2023FDA decision date |
| VITEK 2 AST-Gram Negative Levofloxacin (</=0.125 ->/=8 ug/mL)K222378 · LON | bioMerieux, Inc. | 510(k) | Jun 26, 2023FDA decision date |
| MYLA comprises AST Filters in conjunction with VITEK MS; middleware which connects microbiology laboratory instruments for ID/AST and blood cult…Z-1201-2023 · OUG | Biomerieux Inc | Recall | Mar 2, 2023FDA classification date |
| VITEK® 2 AST-Gram Negative Plazomicin (=0.5 - =16 µg/mL); VITEK® 2 AST-GN Plazomicin (=0.5 - =16 µg/mL); VITEK® 2 AST-GN PlazomicinK223478 · LON | bioMerieux, Inc. | 510(k) | Feb 16, 2023FDA decision date |
| VITEK 2 AST-Gram Negative Cefazolin (<=1 - >=32 ug/mL)K222073 · LON | bioMerieux, Inc. | 510(k) | Feb 9, 2023FDA decision date |
| VITEK® 2 Streptococcus Tetracycline (<=0.25 - >=16 µg/mL)K223481 · LON | bioMerieux, Inc. | 510(k) | Feb 3, 2023FDA decision date |
| VITEK 2 AST-Gram Positive Moxifloxacin (=0.25 - =8 µg/ml), VITEK 2 AST-GP Moxifloxacin (=0.25 - =8 µg/mL), VITEK 2 AST-GP MoxifloxacinK220803 · LON | bioMerieux, Inc. | 510(k) | Jan 27, 2023FDA decision date |
| API LISTERIA 10 STRIPS+10 MEDIA, CATALOG 10300Z-0783-2023 · JTO | Biomerieux Inc | Recall | Jan 4, 2023FDA classification date |
| API 20 E 25 STRIPS, CATALOG 20100Z-0784-2023 · JSS | Biomerieux Inc | Recall | Jan 4, 2023FDA classification date |